Legend Biotech Makes Two Key Executive Changes in Rapid Succession
At the end of July, Legend Biotech quietly updated its executive-team information on its website, completing a key personnel adjustment in its R&D organization. The company did not issue a dedicated announcement to either the Hong Kong Stock Exchange or Nasdaq. Fang Guowei, formerly the company's global president of R&D, was removed from the executive roster. His responsibilities were temporarily assumed by Dr. Qiu Yuhong, whose new title is interim head of R&D and senior vice president of regulatory affairs. Qiu holds a bachelor's degree in biochemistry from Wuhan University, as well as a doctorate and postdoctoral training from Baylor College of Medicine. The supplied source's description of her prior employment is incomplete. The R&D leadership change came only a few days after CEO Huang Ying unexpectedly stepped down on July 24. Within a single month, Legend Biotech had both an interim CEO, Alan Bash, and an interim head of R&D. Industry observers broadly interpreted the changes as a sign that the board preferred to seek long-term successors from outside the company rather than promote internal candidates directly. Legend Biotech's core commercial product, CARVYKTI®, has entered a stable sales phase, while follow-on programs, including next-generation in vivo CAR-T, are entering critical clinical-validation stages. The company appears to be using a leader with both regulatory and R&D experience to oversee development on an interim basis, reflecting the industry's trend toward integrating global regulatory submissions with clinical development. The arrangement prioritizes stability in advancing the pipeline while leaving more time to select a permanent head of R&D. In April 2022, Huang, then Legend Biotech's CEO, personally announced the appointment of Fang as senior vice president and global head of research and early development. Fang took over R&D management responsibilities from Fan Xiaohu, one of the company's founders. The move was viewed at the time as a key signal that Legend Biotech was transitioning from a start-up R&D team into a scaled commercial enterprise. During his four years at Legend Biotech, Fang's responsibilities continued to expand. He was formally promoted to president of R&D in January 2024 and led the creation of an innovative pipeline matrix spanning multiple technology platforms. This ended the company's previous single-product focus on CARVYKTI® and extended its R&D efforts into emerging areas including next-generation in vivo CAR-T, bispecific antibodies and antibody-drug conjugates, laying a framework for product iteration after commercialization. In July 2026, the partnership between Huang and Fang came to an abrupt end. Huang announced her departure as CEO on July 24. One week later, the company's website quietly updated its executive roster, and Fang's information disappeared from the core R&D leadership section. No dedicated announcement was made to the capital markets. The near-simultaneous changes were broadly viewed in the industry as a coordinated management reshuffle rather than two isolated personnel changes. Huang's next move has become a widely discussed topic in the biopharmaceutical industry. Overseas media, citing people familiar with the matter, reported that she is highly likely to join a venture-capital firm focused on new-drug incubation. The specific firm has not been disclosed publicly. That has prompted a further question: Will Fang, whom Huang brought into Legend Biotech and with whom she developed a close commercialization-R&D partnership over four years, follow her into the investment sector? The speculation is based on the fact that from 2022 through 2026, Huang led capital operations and global commercialization, while Fang had full responsibility for early-stage R&D and pipeline expansion. Their roles were highly complementary and formed a stable two-pronged management structure within the company. Their nearly simultaneous departures from key positions, and the close overlap in timing, have given the rumor that they could move together to a new platform substantial practical support. As of now, Legend Biotech has not issued an official announcement about Fang's departure. It has only used its website to identify an interim head of R&D, while Fang has not publicly disclosed a new position. His next move therefore remains a matter of market speculation. For Legend Biotech, which has just completed the commercialization cycle for its first core product and is approaching a critical stage of clinical validation for its next-generation technology pipeline, a change in the head of R&D is significant. The company will need to recalibrate its long-term R&D strategy and conduct a new review of the priorities and resource-allocation ratios across dozens of development programs. That process will be a central variable in determining the pace of innovation over the next several years.
Fang Guowei, formerly the company's global president of R&D, was removed from the executive roster. His responsibilities were temporarily assumed by Dr. Qiu Yuhong, whose new title is interim head of R&D and senior vice president of regulatory affairs. Qiu holds a bachelor's degree in biochemistry from Wuhan University, as well as a doctorate and postdoctoral training from Baylor College of Medicine. The supplied source's description of her prior employment is incomplete.
The R&D leadership change came only a few days after CEO Huang Ying unexpectedly stepped down on July 24. Within a single month, Legend Biotech had both an interim CEO, Alan Bash, and an interim head of R&D. Industry observers broadly interpreted the changes as a sign that the board preferred to seek long-term successors from outside the company rather than promote internal candidates directly.
Legend Biotech's core commercial product, CARVYKTI®, has entered a stable sales phase, while follow-on programs, including next-generation in vivo CAR-T, are entering critical clinical-validation stages. The company appears to be using a leader with both regulatory and R&D experience to oversee development on an interim basis, reflecting the industry's trend toward integrating global regulatory submissions with clinical development. The arrangement prioritizes stability in advancing the pipeline while leaving more time to select a permanent head of R&D.
In April 2022, Huang, then Legend Biotech's CEO, personally announced the appointment of Fang as senior vice president and global head of research and early development. Fang took over R&D management responsibilities from Fan Xiaohu, one of the company's founders. The move was viewed at the time as a key signal that Legend Biotech was transitioning from a start-up R&D team into a scaled commercial enterprise.
During his four years at Legend Biotech, Fang's responsibilities continued to expand. He was formally promoted to president of R&D in January 2024 and led the creation of an innovative pipeline matrix spanning multiple technology platforms. This ended the company's previous single-product focus on CARVYKTI® and extended its R&D efforts into emerging areas including next-generation in vivo CAR-T, bispecific antibodies and antibody-drug conjugates, laying a framework for product iteration after commercialization.
In July 2026, the partnership between Huang and Fang came to an abrupt end. Huang announced her departure as CEO on July 24. One week later, the company's website quietly updated its executive roster, and Fang's information disappeared from the core R&D leadership section. No dedicated announcement was made to the capital markets. The near-simultaneous changes were broadly viewed in the industry as a coordinated management reshuffle rather than two isolated personnel changes.
Huang's next move has become a widely discussed topic in the biopharmaceutical industry. Overseas media, citing people familiar with the matter, reported that she is highly likely to join a venture-capital firm focused on new-drug incubation. The specific firm has not been disclosed publicly. That has prompted a further question: Will Fang, whom Huang brought into Legend Biotech and with whom she developed a close commercialization-R&D partnership over four years, follow her into the investment sector?
The speculation is based on the fact that from 2022 through 2026, Huang led capital operations and global commercialization, while Fang had full responsibility for early-stage R&D and pipeline expansion. Their roles were highly complementary and formed a stable two-pronged management structure within the company. Their nearly simultaneous departures from key positions, and the close overlap in timing, have given the rumor that they could move together to a new platform substantial practical support.
As of now, Legend Biotech has not issued an official announcement about Fang's departure. It has only used its website to identify an interim head of R&D, while Fang has not publicly disclosed a new position. His next move therefore remains a matter of market speculation.
For Legend Biotech, which has just completed the commercialization cycle for its first core product and is approaching a critical stage of clinical validation for its next-generation technology pipeline, a change in the head of R&D is significant. The company will need to recalibrate its long-term R&D strategy and conduct a new review of the priorities and resource-allocation ratios across dozens of development programs. That process will be a central variable in determining the pace of innovation over the next several years.